USE OF OLIGOTIDE FOR THE TREATMENT OF RENAL DISEASES
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 25, 2010
app pub date -
Mar 25, 2008
filing date -
Apr 16, 2007
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present study has demonstrated that heparanase expression and activity was increased in human microvascular endothelial cells and rat kidney epithelial cells growing under hyperglycemia condition, as found in diabetic nephropathy disease. Oligotide was able to: —downregulate the heparanase gene expression; —downregulate the cell surface protein expression; —decrease the heparanase enzymatic activity. Since heparanase is a critical factor in maintaining glomerular basement membrane integrity and is elevated in renal diseases, as for instance diabetic nephropathies. Oligotide should be considered for the management of these diseases.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully